Vaishali Pharma Intrinsic Value
Vaishali Pharma intrinsic value. Vaishali Pharma (VAISHALI) median intrinsic value is ₹13.26 from 9 valuation models (range ₹4–₹20), vs current price ₹6.63 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Analyse Vaishali Pharma ownership pattern to track promoter, FII and institutional holdings.
VAISHALI Valuation Methods Summary — DCF, Graham Number & P/E
Vaishali Pharma intrinsic value across 9 models vs current price ₹6.63 — upside/downside and value range per method. Browse Vaishali Pharma annual reports for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹14.08 | ₹11.26 - ₹16.90 | +112.4% | EPS: ₹0.64, Sector P/E: 22x |
| Book Value Method | asset | ₹16.57 | ₹14.91 - ₹18.23 | +149.9% | Book Value/Share: ₹26.54, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹13.26 | ₹11.93 - ₹14.59 | +100.0% | Revenue/Share: ₹47.69, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹13.26 | ₹11.93 - ₹14.59 | +100.0% | EBITDA: ₹12.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹3.57 | ₹2.86 - ₹4.28 | -46.2% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹4.10 | ₹3.69 - ₹4.51 | -38.2% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹9.89 | ₹8.90 - ₹10.88 | +49.2% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹13.26 | ₹11.93 - ₹14.59 | +100.0% | ROE: 11.6%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹19.55 | ₹17.60 - ₹21.51 | +194.9% | EPS: ₹0.64, BVPS: ₹26.54 |
VAISHALI Intrinsic Value vs Market Price — All Valuation Models
Vaishali Pharma fair value range ₹4–₹20 vs current market price ₹6.63 across 9 valuation models. For current market price and key ratios, visit VAISHALI stock price BSE.
VAISHALI Intrinsic Value Analysis — Undervalued or Overvalued?
Vaishali Pharma median intrinsic value ₹13.26, current price ₹6.63 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of VAISHALI?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Vaishali Pharma (VAISHALI) is ₹13.26 (median value). With the current market price of ₹6.63, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹3.57 to ₹19.55, indicating ₹3.57 - ₹19.55.
Is VAISHALI undervalued or overvalued?
Based on our multi-method analysis, Vaishali Pharma (VAISHALI) appears to be trading below calculated value by approximately 100.0%.
VAISHALI Financial Health — Key Ratios vs Industry Benchmarks
Vaishali Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 11.6% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 7.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.01x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
VAISHALI Cash Flow Quality — Operating & Free Cash Flow
Vaishali Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹0 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹-18 Cr | ₹-18 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |